Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TZ 101

Next Previous
X
Search
Drug Profile

TZ 101

Alternative Names: ASC-101; Ftv1+Gdp-Fucose; GDP-fucose protein O-fucosyltransferase 1 - Targazyme; Peptide-O-fucosyltransferase - Targazyme; TZ-101

Latest Information Update: 28 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator America Stem Cell
  • Developer America Stem Cell; Indiana University School of Medicine; Oregon Health & Science University; Targazyme; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
  • Class Fucosyltransferases; Hexosyltransferases
  • Mechanism of Action Fucosyltransferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease; Haematological malignancies
  • No development reported Diabetic retinopathy; Leukaemia; Multiple myeloma; Multiple sclerosis; Muscle injury; Myelodysplastic syndromes; Myocardial infarction; Peripheral ischaemia; Stomatitis
  • Discontinued Autoimmune disorders; Bone metastases; Stroke

Most Recent Events

  • 28 Feb 2020 No recent reports of development identified for preclinical development in Leukaemia in USA (IV)
  • 28 Feb 2020 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top